Potent and selective TNNI3K inhibitor, orally bioavailable
GSK 329 is a potent and selective TNNI3K (cardiac troponin I-interacting kinase) inhibitor (IC50 = 10 nM). It exhibits selectivity for TNNI3K over human VEGFR2 (40-fold), p38α (80-fold), B-Raf (>200-fold) and displays >100-fold selectivity over 80% of 185 kinases tested.
In vivo
, GSK 329 reduces infarct size, ROS levels, and p38 activation in a mouse model of ischemia/reperfusion cardiac injury. This compound is orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-151207 |
| Réf. fabricant | 30000020 |
| Nom chimique ou matériau | N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea |
| CAS | 1268490-12-5 |
| Quantité | 10 mg |
| Cible | MAPK Inhibitors |
| Formule moléculaire | C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> |
| Pureté | 0.98 |
